Zepbound for Sleep Apnea: What the Approval Actually Covers

The short answer

Zepbound is FDA-approved to treat moderate to severe obstructive sleep apnea in adults with obesity. That indication is printed in section 1 of its label, alongside weight reduction¹.

Wegovy and Ozempic are not approved for it. Neither label carries a sleep apnea indication^2,3. If you have been told "GLP-1s help with sleep apnea," that is a class-level generalization; the approval belongs to one drug.

That distinction is the practical one, because an FDA indication is what a prior-authorization review is built around.

What the trials found

Two 52-week randomized, placebo-controlled trials, 469 adults with moderate-to-severe OSA and obesity. Study 5 enrolled people not using PAP therapy; Study 6 enrolled people already on PAP. People with type 2 diabetes were excluded. Doses were escalated over up to 20 weeks to 10 mg or 15 mg¹.

These were not mild cases. Mean starting AHI was around 50 events an hour, and roughly two thirds of participants had severe OSA¹.

Read the fourth row twice. In the group already using PAP, half of the people on Zepbound ended the year with their apnea in remission or reduced to mild and non-symptomatic, against 14.3% on placebo¹.

What it does not say

• It is not a replacement for your CPAP. Study 6 tested the drug alongside PAP therapy, not instead of it. Nothing in these results tells you to stop using a machine that is working, and that is a decision for your sleep physician.
• It was studied in obesity. The indication is specifically for adults with obesity — this is not an approval for sleep apnea generally.
• Both trials were mostly men — 67% in Study 5, 72% in Study 6¹. The result is likely to hold for women, but women were the minority of the evidence.
• People with type 2 diabetes were excluded¹, so the trials do not describe that group.

The coverage question

This is where the approval matters most, and where you should be careful with anything you read, including here.

What is verifiable: the FDA indication exists, and it is for the drug's own trials in OSA. What is not in the label, and what nobody can tell you in the abstract, is what your specific plan will do. Formulary rules, prior-authorization criteria and Medicare policy are decided by plans and change; none of that comes from the prescribing information.

So the useful moves are practical:

• Ask for the OSA criteria specifically, not the weight-loss ones. Many plans exclude weight-loss drugs while covering the same drug for an approved medical indication. Those are two different review pathways and they can produce different answers for the same prescription.
• Get the sleep study in the file. A documented AHI is the number the criteria are usually written around, and moderate-to-severe means an AHI of 15 or more.
• Have your prescriber write to the indication. A request that says "obstructive sleep apnea with obesity" is answering a different question from one that says "weight loss."
• Ask for the denial reason in writing if it is refused, then appeal against that specific criterion. Our prior authorization walkthrough covers the sequence. If the answer is a flat exclusion, the cheapest GLP-1 board prices the cash-pay route over a full year.

Worth knowing before you ask

The trials ran for a year, and the AHI improvement came alongside 17–20% weight loss¹. This is not a fast fix; it is a year-long treatment whose benefit tracked substantial weight change. If you are hoping to be off PAP by winter, that is not what was demonstrated.

None of this is medical advice, and sleep apnea is a condition where untreated risk is real. Do not change how you use a PAP machine on the strength of a web page.